Eric Velazquez, MD
Robert W. Berliner Professor of Medicine (Cardiology)Cards
About
Titles
Robert W. Berliner Professor of Medicine (Cardiology)
Chief, Cardiovascular Medicine; Deputy Director, Clinical Trials Innovation, Yale Center for Clinical Investigation (YCCI); Co-Chair, Clinical and Translational Research Oversight Committee; President’s contingency planning committee, Clinical Practice/Clinical Research Subcommittee
Positions outside Yale
Chief, Cardiovascular Medicine, Yale New Haven Hospital, Yale New Haven Hospital; Physician-in-Chief, Heart and Vascular Center, Yale New Haven Health System, Yale New Haven Health System
Biography
Eric J. Velazquez, MD, the Robert W. Berliner Professor of Medicine, is an internationally recognized authority in heart failure, cardiovascular clinical trials, and cardiac imaging.
Velazquez serves as the section chief for Cardiovascular Medicine for Yale School of Medicine and the Physician-in-Chief of the Heart and Vascular Center for Yale New Haven Health where he coordinates a high-volume enterprise and an outstanding group of clinician-investigators, physician scientists, and staff who make important contributions across patient care, research and educational domains. He leads more than 150 specialists who focus on every area of cardiac medicine, tapping into a broad array of tools, technologies, and expertise.
Additionally, he is the Deputy Director, Clinical Trials Innovation at the Yale Center for Clinical Investigation. Velazquez chose to pursue a career in cardiovascular medicine twenty years ago and through key leadership positions, he has pursued clinical, research, and methodologic interests and facilitated multicenter clinical research programs and quality initiatives with substantive focus and impact on vulnerable and underserved populations at high medical risk, and has honed the administrative skills required to implement challenging programs in diverse settings globally. Today, much of his research and clinical work focuses on the intersection between heart failure and coronary heart disease. As a clinical investigator, he has made major contributions in the design, development, and implementation of landmark clinical trials that have altered international guidelines and the treatment of patients with chronic heart failure. These programs have established the evidence for best practice standards, modified treatment guidelines, and have had a direct impact on the U.S. public health.
Appointments
Cardiovascular Medicine
Section ChiefDualCardiovascular Medicine
ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Duke University School of Medicine (2001)
- Research Fellow
- Duke University School of Medicine (2001)
- Fellow
- Duke University School of Medicine (2000)
- MD
- Albert Einstein College of Medicine (1997)
- Senior Assistant Resident
- Duke University School of Medicine, (1997)
- Junior Assistant Resident
- Duke University School of Medicine (1996)
- Intern
- Duke University School of Medicine (1995)
- MD
- Yeshiva University (1994)
- BA
- Williams College, Psychology (1988)
Research
Publications
2026
Association of Guideline-Directed Medical Therapy for Heart Failure and Major Amputation Rates in Patients With Chronic Limb-Threatening Ischemia and Concomitant Heart Failure
Kwaah P, Mensah S, Tabot-Ntoung C, Carboo A, Hu J, Tong G, Velazquez E, Altin S. Association of Guideline-Directed Medical Therapy for Heart Failure and Major Amputation Rates in Patients With Chronic Limb-Threatening Ischemia and Concomitant Heart Failure. The American Journal Of Cardiology 2026, 273: 35-43. PMID: 42264013, DOI: 10.1016/j.amjcard.2026.06.002.Peer-Reviewed Original ResearchBayesian Inference for Cluster‐Randomized Trials With Multivariate Outcomes Subject to Both Truncation by Death and Missingness
Tong G, Li C, Velazquez E, Harhay M, Li F. Bayesian Inference for Cluster‐Randomized Trials With Multivariate Outcomes Subject to Both Truncation by Death and Missingness. Statistics In Medicine 2026, 45: e70588. PMID: 42179351, DOI: 10.1002/sim.70588.Peer-Reviewed Original ResearchDiscordance of Aortic Valve Area Indexed to Actual and Ideal Body Surface Area in Aortic Stenosis
Reinhardt S, Singh J, Shah N, McNamara R, Sugeng L, Agarwal V, Hur D, Lombo B, Bellumkonda L, Akintoye E, Shkolnik E, Velazquez E, Faridi K. Discordance of Aortic Valve Area Indexed to Actual and Ideal Body Surface Area in Aortic Stenosis. Journal Of The American Society Of Echocardiography 2026 PMID: 41997251, DOI: 10.1016/j.echo.2026.03.013.Peer-Reviewed Original ResearchSurgical Risk and Revascularization—An Update
Marquis-Gravel G, Tong G, Dodd M, Clayton T, Ryan M, Docherty K, Williams A, Sun J, Fremes S, Lansky A, Velazquez E, Perera D, Petrie M, Rouleau J. Surgical Risk and Revascularization—An Update. Journal Of The Society For Cardiovascular Angiography & Interventions 2026, 5: 104392. PMID: 42111102, PMCID: PMC13154621, DOI: 10.1016/j.jscai.2026.104392.Commentaries, Editorials and Letters
2025
Management of Ischemic Heart Disease in Patients With Heart Failure JACC: Heart Failure Position Statement
Mielniczuk L, Ahmad T, Borovac J, Brown K, Cooper L, Fida N, Hochman J, Al Lamee R, Lawton J, Narang N, Perera D, Petrie M, Rajagopalan N, Reza N, Stone P, Tamis-Holland J, Velazquez E. Management of Ischemic Heart Disease in Patients With Heart Failure JACC: Heart Failure Position Statement. JACC Heart Failure 2025, 13: 102731. PMID: 41338831, PMCID: PMC13038397, DOI: 10.1016/j.jchf.2025.102731.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsRevascularization in Ischemic Left Ventricular Dysfunction A Pathophysiology-Guided, Evidence-Based Approach
Ryan M, Truesdell A, Murphy G, Ezad S, Fremes S, Lansky A, Omerovic E, Windecker S, Velazquez E, Petrie M, Kirtane A, Stone G, Perera D. Revascularization in Ischemic Left Ventricular Dysfunction A Pathophysiology-Guided, Evidence-Based Approach. JACC Cardiovascular Interventions 2025, 18: 2977-2994. PMID: 41146481, DOI: 10.1016/j.jcin.2025.10.030.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsClinical Decision-MakingCoronary Artery BypassDecision Making, SharedEvidence-Based MedicineHumansMyocardial IschemiaPatient SelectionPercutaneous Coronary InterventionRecovery of FunctionRisk AssessmentRisk FactorsStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftVentricular Function, LeftSurgical Risk and Long-Term Mortality With PCI and CABG in Ischemic Left Ventricular Systolic Dysfunction
Marquis-Gravel G, Tong G, Dodd M, Clayton T, Ryan M, Docherty K, Williams A, Sun J, Fremes S, Lansky A, Velazquez E, Perera D, Petrie M, Rouleau J. Surgical Risk and Long-Term Mortality With PCI and CABG in Ischemic Left Ventricular Systolic Dysfunction. Journal Of The Society For Cardiovascular Angiography & Interventions 2025, 4: 103820. PMID: 41040436, PMCID: PMC12485539, DOI: 10.1016/j.jscai.2025.103820.Peer-Reviewed Original ResearchDays Alive Out of Hospital for Patients with Left Ventricular Dysfunction From the STICH Trial
Faridi K, Huang H, Parise H, Ahmad T, Mori M, Chung M, Yeh R, Petrie M, Panza J, Rouleau J, Dabrowski R, Velazquez E. Days Alive Out of Hospital for Patients with Left Ventricular Dysfunction From the STICH Trial. JACC Heart Failure 2025, 13: 867-869. PMID: 40335237, DOI: 10.1016/j.jchf.2025.02.019.Commentaries, Editorials and LettersCoronary artery bypass surgery improves restricted mean survival time in patients with ischemic cardiomyopathy
Reinhardt S, Huang H, Parise H, Ahmad T, Velazquez E, Faridi K. Coronary artery bypass surgery improves restricted mean survival time in patients with ischemic cardiomyopathy. American Heart Journal Plus Cardiology Research And Practice 2025, 54: 100538. PMID: 40485767, PMCID: PMC12142554, DOI: 10.1016/j.ahjo.2025.100538.Peer-Reviewed Original ResearchEffects of angiotensin-neprilysin inhibition in women vs men: Insights from PARAGLIDE-HF
Rambarat P, Erickson T, Cyr D, Ward J, Hernandez A, Morrow D, Starling R, Velazquez E, Zieroth S, Williamson K, Solomon S, Mentz R. Effects of angiotensin-neprilysin inhibition in women vs men: Insights from PARAGLIDE-HF. American Heart Journal 2025, 288: 41-51. PMID: 40174692, DOI: 10.1016/j.ahj.2025.03.017.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Eric J. Velazquez, MD, is chief of cardiovascular medicine for Yale Medicine and Yale New Haven Hospital, physician-in-chief of the Yale New Haven Health System Heart and Vascular Center. He leads more than 150 specialists who focus on every area of cardiac medicine, tapping into a broad array of tools, technologies, and expertise.
A practicing cardiologist himself, Dr. Velazquez is an internationally recognized authority in heart failure, cardiovascular clinical trials, and cardiac imaging, and he has a passion for treating patients with coronary disease. He says the earlier a patient seeks help for fatigue, shortness of breath, and other key symptoms, the more a cardiologist can help.
“We are fortunate today that medical and device therapies, as well as surgical approaches that were only being tested a couple of decades ago, are now available to patients routinely,” says Dr. Velazquez, who was inspired to become a cardiologist, in part, by his own family history of the disease. “I tell patients, ‘Don’t dismiss your symptoms. If we diagnose your disease before it becomes advanced, there's so much more we can apply to your care that might make your future life much better.’”
The Robert W. Berliner Professor of Medicine at the Yale School of Medicine, Dr. Velazquez has been involved in such areas as population health, community care, genetics, discovery science, and translational and clinical research—all of which he says feed into better care for heart disease. “For example, in population health, we track patients who have had heart attacks and other heart-related problems, and this has given us information that we can use to better evaluate health and mitigate the progression of disease,” he says.
Dr. Velazquez has made major contributions as a clinical investigator in the design, development, and implementation of landmark clinical trials that have altered international guidelines and the treatment of patients with chronic heart failure. He sees this type of work thriving at Yale. “I’m very fortunate to be at the helm of a group of doctors who wake up every day and think about the patients they're going to see—and at the same time, pay attention to what it is about each encounter that they can look at critically, improve upon, and maybe apply in a research setting with the goal of bringing it back to a future patient,” he says.
Clinical Specialties
Yale Medicine News
News
News
- June 29, 2026
Michael Nanna and Sara Tabtabai Join Yale Cardiovascular Medicine Fellowship Program Leadership Team
- June 24, 2026
Breaking Down Silos to Understand Cardiometabolic Diseases
- March 18, 2026
Advancing Research and Care To Improve Maternal Heart Health
- February 13, 2026
Changing the Landscape of Carotid Artery Disease Treatment
Get In Touch
Contacts
Yale University
PO Box 208017
New Haven, CT 06520-8017
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.